The historical rank and industry rank for Clearside Biomedical's Days Payable or its related term are showing as below:
CLSDQ'
s Days Payable Range Over the Past 10 Years
Min: 1407.04 Med: 1781.16 Max: 4479.21
Current: 1407.04
During the past 12 years, Clearside Biomedical's highest Days Payable was 4479.21. The lowest was 1407.04. And the median was 1781.16.
CLSDQ's Days Payable is ranked better than 88.86% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs CLSDQ: 1407.04
Clearside Biomedical's Days Payable
stayed the same
from Sep. 2024 (0.00) to Sep. 2025 (0.00).
stayed the same
Clearside Biomedical Days Payable Related Terms
Clearside Biomedical Days Payable Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLSDQ vs LYRA, EVFM, ATXI: Days Payable Comparison
For the Biotechnology subindustry, Clearside Biomedical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearside Biomedical Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Days Payable distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Clearside Biomedical's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (CLSDQ) has a Days Payable of 0.00 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Clearside Biomedical and its competitors. Over the past decade, Clearside Biomedical's Days Payable has ranged from 1,407.04 to 4,479.21. According to the industry distribution chart, Clearside Biomedical ranks #78 out of 700 companies in the Biotechnology industry, placing it in the top 11.1%.
Is Clearside Biomedical's Days Payable too high?
Clearside Biomedical's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,407.04 to a high of 4,479.21. Based on the distribution chart, Clearside Biomedical ranks #78 out of 700 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Days Payable compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #78 out of 700 companies for Days Payable. This places Clearside Biomedical in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Historically, Clearside Biomedical's own Days Payable has ranged from 1,407.04 to 4,479.21 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Clearside Biomedical and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearside Biomedical's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current Days Payable is 0.00. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current Days Payable is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (CLSDQ) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34.
GuruFocus considers Clearside Biomedical to be Possible Value Trap.
Key valuation signals for CLSDQ:
Days Payable: 0.00
GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for CLSDQ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLSDQ has been successfully added to your 
